COMPANY PROFILE

Pelemed

Explore full profile

Innovative precision therapies for refractory cancers and viral infectious diseases using AI-driven drug discovery

Seoul, South KoreaFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Pelemed

PeLeMed is a biotechnology company dedicated to discovering and developing innovative therapeutics for incurable diseases, particularly focusing on refractory cancers and viral infectious diseases. Utilizing a unique precision drug design technology and an AI-driven high-efficiency drug discovery platform, PeLeMed aims to create precision therapies that significantly improve patient outcomes. The company operates in the biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies. PeLeMed's business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic candidates. Revenue is generated through funding, grants, and partnerships with larger pharmaceutical firms. The company has secured multiple rounds of funding, including Series A and bridge funding, and has initiated several clinical trials for its drug candidates.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Seoul, South Korea
Employees: 2
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2023	$9.2M	$37M	Undisclosed	—
SERIES AEquity / VC	Dec 2020	$5.4M	$22M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Pelemed website traffic

Latest recorded traffic for Pelemed is 1.1K monthly website visits, up 93% over the last three months. Pelemed's team grew 0% over the past year.

Latest monthly visits1.1K 3-month web change+93% 1-year team growth0%

Monthly website visitsAug 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
3535PharmaAdvancing therapeutic biologics to treat cardiopulmonary and metabolic diseases	Montreal, Canada	Acquired
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational
MBMICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications	Solihull, United Kingdom	Operational